FDA BIMO (Bioresearch Monitoring) Program

The FDA Bioresearch Monitoring (BIMO) Program is the umbrella inspection and data-audit program FDA uses to monitor the conduct and reporting of FDA-regulated research — not a single inspection type but a program that spans several distinct categories of regulated entity, each covered by its own compliance program manual. Its stated purpose is twofold: to assure the quality and integrity of data submitted to FDA in support of new product approvals and marketing applications, and to protect the rights, safety, and welfare of the human subjects (and animals, in nonclinical studies) involved in that research. A “BIMO inspection” is a shorthand for an on-site inspection conducted under one of the program’s specific compliance-program tracks, not a single undifferentiated inspection type.

What BIMO Covers

BIMO’s compliance programs address inspections across several categories of regulated entity, each with its own program-specific inspection guide:

• Clinical investigators — inspected for compliance with Good Clinical Practice (GCP) and the specific protocol, verifying that source data support what was submitted to FDA and that informed consent and protocol requirements were followed.
• Sponsors, monitors, and Contract Research Organizations (CROs) — inspected to verify sponsor oversight obligations, monitoring practices, and safety-reporting compliance were actually carried out as required.
• Institutional Review Boards (IRBs) — inspected for compliance with the human-subject-protection regulations governing review, approval, and continuing oversight of research involving human subjects. See CASRAI’s IRB (Institutional Review Board) entry.
• Nonclinical (preclinical) testing laboratories — inspected for compliance with Good Laboratory Practice (GLP) regulations governing the animal and in-vitro safety studies that support an investigational or marketing application. See CASRAI’s Good Laboratory Practice (GLP) entry.
• In vivo bioequivalence testing facilities — inspected in support of generic drug applications that rely on bioequivalence data.
• Radioactive Drug Research Committees (RDRCs), postmarketing adverse drug experience (PADE) reporting, and Risk Evaluation and Mitigation Strategies (REMS) reporting — narrower, program-specific compliance tracks within the broader BIMO umbrella.

Because product-specific expertise differs by FDA center, BIMO inspections are carried out on behalf of the center with jurisdiction over the product at issue — CDER for drugs, CBER for biologics, and CDRH for medical devices each maintain their own BIMO compliance programs and inspection assignments, while the on-site field-inspection function itself sits within FDA’s Office of Inspections and Investigations (OII), the successor to the Office of Regulatory Affairs’ (ORA) field-inspection role following FDA’s October 2024 reorganization.

Inspection Types Within BIMO

Not every BIMO inspection is triggered the same way. FDA’s own BIMO compliance programs describe several inspection categories:

• Routine (surveillance) inspections — scheduled as part of FDA’s ordinary oversight of ongoing regulated activity, often prompted by a pending marketing application or high enrollment in a pivotal trial, or on a periodic basis for establishments with continuing regulated activity such as an active IRB or nonclinical laboratory.
• Directed (data-audit) inspections — focused specifically on verifying the data underlying a particular marketing submission, rather than a general review of the site’s overall operations.
• For-cause inspections — triggered by a specific complaint, a required safety report, a data-integrity concern, or another signal that prompts FDA to investigate a specific problem; these may be announced with little notice or conducted unannounced.
• Compliance follow-up inspections — conducted to verify that corrective actions committed to after a prior inspection were actually implemented.

This is the same routine-versus-for-cause distinction CASRAI’s Inspection Readiness entry discusses from the site’s perspective: a site that only prepares once a routine visit is scheduled has no comparable window to prepare for a for-cause inspection, which is the operational case for treating readiness as continuous rather than reactive.

Inspection Outcomes: NAI, VAI, and OAI

A closed, classified BIMO inspection resolves to one of three outcomes, the same three-tier system FDA applies across all of its inspection programs:

• No Action Indicated (NAI) — no objectionable conditions were found.
• Voluntary Action Indicated (VAI) — objectionable conditions were observed, but FDA is not recommending regulatory or administrative action; a Form FDA-483 is typically issued at the close of the inspection.
• Official Action Indicated (OAI) — the facility or investigator is in an unacceptable state of compliance and regulatory or administrative action is recommended.

For a clinical investigator specifically, an OAI classification can lead to further FDA action up to and including disqualification proceedings, which bar the individual from serving as a clinical investigator on FDA-regulated studies. Closed, classified BIMO inspection outcomes for a given facility can be looked up in FDA’s public classification database — see CASRAI’s FDA Inspection Database guide for how to search it and what it does and does not contain.

Frequently Asked Questions

Is BIMO the same thing as a GCP inspection?

Related but not identical. Good Clinical Practice (GCP) is the quality standard FDA inspects clinical investigators, sponsors, monitors, and IRBs against; BIMO is the FDA program under which those inspections — along with GLP nonclinical-laboratory inspections and several other tracks — are conducted. A “BIMO inspection of a clinical investigator” is, in practice, a GCP inspection carried out under the BIMO program.

Does BIMO inspect drug and device manufacturing facilities under cGMP?

No. Manufacturing-facility inspections under current Good Manufacturing Practice (cGMP) are a separate FDA compliance program from BIMO. BIMO’s scope is research conduct and data integrity — clinical investigators, sponsors/CROs/monitors, IRBs, nonclinical (GLP) laboratories, bioequivalence testing, and the narrower RDRC/PADE/REMS tracks — not product manufacturing. A site or sponsor operating a manufacturing facility can separately be subject to a cGMP inspection, but that inspection falls outside BIMO itself.

Who receives the results of a BIMO inspection?

The inspected clinical investigator, sponsor, IRB, or facility receives any Form FDA-483 issued at the close of the inspection directly. The inspection’s final classification (NAI, VAI, or OAI) is later published, once finalized, in FDA’s public Inspection Classification Database, searchable by firm name, location, or FEI number.

Can a sponsor be inspected under BIMO even if no problems are suspected?

Yes. Routine surveillance inspections are a normal, expected part of the BIMO program and are not, by themselves, a sign that FDA suspects a specific problem — they are commonly triggered simply by a pending marketing application or by an establishment’s ongoing regulated activity, such as an active IRB.

Related CASRAI Resources

• Inspection Readiness — the continuous state of preparedness a site maintains for a BIMO or other regulatory inspection
• FDA Form 483 — the inspectional-observations document typically issued at a VAI or OAI outcome
• FDA Inspection Database: How to Search Inspection Classifications
• IRB (Institutional Review Board)
• ICH GCP (Good Clinical Practice)
• Good Laboratory Practice (GLP)
• 21 CFR Part 11: Electronic Records & Signatures
• FDA (Food and Drug Administration)
• Clinical Research Administration — cluster hub

References

• FDA, Bioresearch Monitoring Program Information
• FDA, Bioresearch Monitoring Program (BIMO) Compliance Programs
• FDA, Inspection Classifications